“Our aim was to evaluate the incidence and risk factors for complications associated with CVAD usage in a retrospective nationwide multicentre study in five Finnish Paediatric Haemophilia Treatment Centers” Vepsäläinen et al (2015).
Reference:
Vepsäläinen, K., Lassila, R., Arola, M., Lähteenmäki, P., Möttönen, M., Mäkipernaa, A. and Riikonen, P. (2015) Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland. Haemophilia. March 31st. [epub ahead of print].
[ctt tweet=”Central venous access devices in children with haemophilia http://ctt.ec/f766q+ @ivteam #ivteam” coverup=”f766q”]
Abstract:
Children with haemophilia require venous access for regular infusion of coagulation factors. A central venous access device (CVAD) ensures long-term access but associates with infectious and non-infectious complications with proposed risk factors of young age at initial CVAD implantation and presence of an inhibitor. Our aim was to evaluate the incidence and risk factors for complications associated with CVAD usage in a retrospective nationwide multicentre study in five Finnish Paediatric Haemophilia Treatment Centers. Our study investigated 106 CVADs in 58 patients with 137 971 CVAD days. The median access survival was 1159 CVAD days, and most often a malfunction led to CVAD removal after a long survival (median of 1640 CVAD days). We detected a very low bloodstream infection rate (0.12/1000 CVAD days). The presence of neutralizing inhibitor was a significant risk factor for infection. Heparin vs. saline flushing did not influence the CVAD outcome. We detected a lower infection rate than previously reported, although 90% of the patients were very young (
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]